Loading stock data…
12,300pGBX+404.00p (+3.40%)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
AstraZeneca PLC in the Healthcare sector is trading at 12,300p with a market capitalization of $186.1B. Wall Street consensus targets 15,925p (23 analysts), implying a +29.5% move over the next 12 months. The stock is currently 22% below its 52-week high of 15,732p, remaining 8.8% below its 200-day moving average. Risk note: MACD remains below its signal line. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | $14.46B↓ | $15.19B↓ | $15.50B↑ | $15.29B↓ | $15.38B |
| Gross Profit | $11.98B↓ | $12.39B | $12.38B↓ | $12.61B↓ | $12.86B |
| Operating Income | $3.51B↓ | $3.58B↑ | $2.98B↓ | $4.25B↑ | $3.16B |
| Net Income | $2.45B↓ | $2.53B↑ | $2.33B↓ | $3.08B↑ | $2.51B |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...